Immunovant, Inc. (IMVT)

NASDAQ: IMVT · USD

$29.4

+0.55 (+1.9%)· Recorded snapshot

Market cap	6.1B
Net income (ttm)	-538.2M
EPS (ttm)	-$2.82
Shares out	206.6M
Volume	1,007,127
Beta	0.84

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -538.2M
EPS (ttm): -$2.82
Market cap: 6.1B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-80.1

P25 n/aP50 n/aP75 n/a

ROIC-52.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All IMVT indicators

Market & fundamental data

Available fields

178

Groups with data

Currency

USD

Showing 178 of 178 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001764013
Company name	Immunovant, Inc.
Country	United States
Country code	US
CUSIP number	45258J102
Earnings date	2026-11-09
Earnings time	bmo
Employees	315
Employees change	-47
Employees growth	-12.98%
Enterprise value	$5.3B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	March
Founded	2018
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US45258J1025
Last 10-K release date	2026-05-20
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$6.1B
Market cap category	Mid-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$29.43
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	IMVT
U.S. state	North Carolina
Website	https://immunovant.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-9.57%
FCF / EV yield	-7.94%
FCF yield	-6.89%
P/B ratio	8.1x
Price / tangible book value	8.18x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.7M
ROA	-46.73%
ROA (5Y)	-31.43%
ROCE	-76.97%
ROE	-80.1%
ROE (5Y)	-53.46%
ROIC	-52.64%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-8,000
Depreciation and amortization	$394,000
EBIT	$-566M
EBITDA	$-565.6M
EPS	$-2.82
FCF per share	$-2.01
Financing cash flow	$612.9M
Free cash flow	$-414.3M
Free cash flow minus SBC	$-465.3M
Income taxes	$-698,000
Investing cash flow	$-8,000
Net cash flow	$198.9M
Net income	$-538.2M
Operating cash flow minus SBC	$-465.3M
Operating income	$-566M
Stock-based compensation	$51M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$3.57
Debt / equity	0
Long-term assets	$1.3M
Long-term liabilities	$0
Net cash (debt)	$797.8M
Net cash / market cap	13.26%
Net cash growth	33.21%
Net debt / equity	-1.08
Piotroski F-Score	1
Property, plant and equipment	$351,000
Shareholders' equity	$735.4M
Tangible book value	$735.4M
Tangible book value per share	$3.57
Total assets	$852.5M
Total cash	$797.8M
Total debt	$0
Total liabilities	$117.1M
WACC	8.87%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$851.2M
Current liabilities	$117.1M
Current ratio	7.27
Net working capital	$-63.7M
Quick ratio	6.82
Working capital	$734.1M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-21.12%
Dividend yield	0%
Shareholder yield	-21.12%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$34.02
1D price change	1.9%
1M price change	-12.4%
1M total return	-12.4%
1W price change	2.03%
1W total return	2.03%
1Y price change	36.12%
1Y return CAGR	36.15%
1Y total return	36.12%
20-day SMA	$29.70
200-day SMA	$32.02
3M price change	-27.24%
3M total return	-27.24%
3Y price change	-12.72%
3Y return CAGR	-4.43%
3Y total return	-12.72%
50-day SMA	$35.16
50-day SMA vs 200-day SMA	50over200
52-week high	$45.42
52-week high date	2026-08-19
52-week low	$21.05
52-week low date	2025-10-28
5Y price change	272.54%
5Y return CAGR	30.09%
5Y total return	272.54%
6M price change	1.92%
6M total return	1.92%
All-time high	$53.75
All-time high date	2020-11-18
All-time low	$3.15
All-time low date	2022-06-13
Average true range (ATR)	$1.22
Average volume	1.4M
Beta (1Y)	1.47
Beta (2Y)	1.3
Beta (5Y)	0.84
Change from 52-week high	-35.2%
Change from 52-week low	39.81%
Change from all-time high	-45.73%
Change from all-time low	827.5%
Change from open	3.55%
Day's gap	-1.59%
Dollar volume	$29.6M
High price	$29.45
Low price	$28.42
Monthly RSI	52.14
Open price	$28.42
Position in 52-week range	98.06%
Premarket change	0.1%
Premarket close	$28.88
Premarket price	$28.91
Premarket volume	1.3K
Previous close	$28.88
Price vs 150-day SMA	-14.26%
Price vs 20-day SMA	-1.79%
Price vs 200-day SMA	-8.89%
Price vs 50-day SMA	-17.04%
Relative volume	0.74
RSI	38.71
Sharpe ratio	0.73
Sharpe ratio (3Y)	0.1
Sharpe ratio (5Y)	0.59
Sortino ratio	1.59
Sortino ratio (3Y)	0.27
Sortino ratio (5Y)	1.3
Volume	1M
Weekly RSI	42.31
YTD price change	14.75%
YTD total return	14.75%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	91.8M
Float percentage	44.43%
Shares change (QoQ)	0.9%
Shares change (YoY)	21.12%
Shares held by insiders	0.71%
Shares held by institutions	54.76%
Shares outstanding	206.6M
Short % of float	19.91%
Short % of shares	8.85%
Short ratio	11.3 days

Deeper analysis on IMVT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this IMVT report

Is a complete IMVT research report available?

No complete published report is available for Immunovant, Inc. (IMVT) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Immunovant, Inc. (IMVT)

Price

Financial snapshot

Fair-value bridge

Latest news · IMVT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All IMVT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on IMVT

Frequently asked questions